FDA (Drugs) recall action 76664
The FDA (Drugs) publishes a recall like this one as 9 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 9 pages.
Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib
The agency’s own wording, quoted from the enforcement report.
Alvogen, Inc. is recalling Adalat CC (nifedipine) 90 mg extended-release tablets because residual sorafenib powder was found in the manufacturing equipment's inlet air duct.
Alvogen, Inc. is recalling specific lots of Adalat CC (nifedipine) Extended-Release Tablets due to cross-contamination with sorafenib powder.
Alvogen Inc. is recalling Nifedipine Extended-Release Tablets, 90 mg, due to cross-contamination with sorafenib powder found in the inlet air duct.
Alvogen, Inc. is recalling Nifedipine Extended-Release Tablets, 60 mg, due to cross-contamination with sorafenib powder found in the manufacturing facility's inlet air duct.
Alvogen, Inc. is recalling Adalat CC (nifedipine) Extended Release Tablets due to cross-contamination with sorafenib powder found in the manufacturing facility.
Alvogen, Inc. is recalling Adalat CC (nifedipine) Extended Release Tablets 30 mg due to cross-contamination with sorafenib powder.
Alvogen, Inc. is recalling Nifedipine Extended-Release Tablets, 30 mg, due to cross-contamination with sorafenib powder found in the manufacturing facility's inlet air duct.
Alvogen is recalling specific lots of Adalat CC (nifedipine) extended-release tablets due to cross-contamination with sorafenib powder.
Alvogen, Inc. is recalling Adalat CC (nifedipine) 60 mg extended-release tablets because residual sorafenib powder was found in the manufacturing facility's inlet air duct.